Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Shares Issued (2016 - 2025)

CytomX Therapeutics' Shares Issued history spans 11 years, with the latest figure at $16.3 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 3890.7% year-over-year to $16.3 million; the TTM value through Dec 2025 reached $109.7 million, changed N/A, while the annual FY2025 figure was $811000.0, N/A changed from the prior year.
  • Shares Issued reached $16.3 million in Q4 2025 per CTMX's latest filing, down from $93.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $107.7 million in Q1 2021 to a low of -$106.0 million in Q2 2021.
  • Average Shares Issued over 5 years is $7.6 million, with a median of $190000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: skyrocketed 4893.6% in 2021, then plummeted 15420.0% in 2023.
  • A 5-year view of Shares Issued shows it stood at -$105.2 million in 2021, then skyrocketed by 100.18% to $190000.0 in 2022, then tumbled by 15420.0% to -$29.1 million in 2023, then skyrocketed by 98.52% to -$430000.0 in 2024, then soared by 3890.7% to $16.3 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Shares Issued are $16.3 million (Q4 2025), $93.2 million (Q3 2025), and $177000.0 (Q2 2025).